Back to Journals » Journal of Inflammation Research » Volume 17

Expression and Signiffcance of KIM-1, NGAL, and HO-1 in Patients with Acute Kidney Injury After Cardiac Valve Replacement [Letter]

Authors Song Y, Gu J

Received 19 February 2024

Accepted for publication 23 February 2024

Published 26 February 2024 Volume 2024:17 Pages 1265—1266

DOI https://doi.org/10.2147/JIR.S464836

Checked for plagiarism Yes

Editor who approved publication: Professor Ning Quan



Yanyan Song, Jiwei Gu

Department of Cardiovascular Surgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, People’s Republic of China

Correspondence: Yanyan Song, Department of Cardiovascular Surgery, General Hospital of Ningxia Medical University, No. 804 Shengli South Street, Xingqing District, Yinchuan, 750004, People’s Republic of China, Email [email protected]


View the original paper by Dr Zhang and colleagues


Dear editor

We are interested in the recently published research article1 entitled “Expression and Significance of KIM-1, NGAL and HO-1 in Patients with Acute Kidney Injury After Cardiac Valve Replacement” in the Journal of Inflammation Research.We appreciate and congratulate the novel research work conducted by the Zhang B. team.

The authors aimed to investigate the changes and significance of perioperative expression levels of kidney injury molecule-1 (KIM-1), neutrophil gelatinase-related lipocalin (NGAL), and heme oxygenase-1 (HO-1) in patients with acute kidney injury (AKI) after cardiac valve replacement under cardiopulmonary bypass(CPB).The investigators selected 80 patients, were divided into AKI group and non-AKI group based on the postoperative occurrence of AKI.The expression levels of urinary KIM-1, NGAL, serum creatinine(Scr), urea nitrogen, and HO-1 were compared between the two groups before surgery and at 12 h, 24 h, and 48 h after surgery.The levels of KIM-1, NGAL, and HO-1 in patients after CPB cardiac valve replacement are increased, but the increase in patients in AKI group is more significant. The authors concluded that AKI can easily occur after cardiac valve replacement and postoperative expression levels of KIM-1, NGAL, and HO-1 can be early warning indicators of postoperative AKI.

We acknowledge the validity of the research findings, but we have identified specific concerns that need attention.

Firstly, the selected cases in the study all were underway cardiac valve replacement with CPB, which lacked the comparison of beating-heart and arrested-heart postoperative AKI.According to literature report,2 in patients undergoing beating-heart and arrested-heart replacement of mitral valve, the two groups increased KIM-1 at 30 minutes after the start of CPB, but the beating-heart group had recovered to normal level 72 h after surgery, while the arrested-heart group still failed to return to the preoperative level after 72 h. The concentration of KIM-1 in the beating-heart group significantly lower than that in the arrested-heart group (P<0.05).Non-stop jumping operation ensures effective kidney perfusion to some extent, suggesting that the beating-heart cardiac surgery might reduce renal dysfunction.

Secondly, the study did not explore the correlation of perioperative NGAL, KIM-1, HO-1 and sCr levels, and could further apply the ROC curve to evaluate the value of the above acute kidney injury detection indicators for the early diagnosis of AKI after CPB heart valve replacement.According to literature report,3 The AUC was 0.829 when urinary KIM-1 was performed to diagnose AKI at 2h after CPB.When 259 ng/L was taken as the diagnostic cut-off value for AKI, its sensitivity and specificity for the diagnosis of AKI were respectively 83.3% and 62.5%.

The occurrence of AKI after cardiac surgery is a complex process of multifactor participation and mutual influence,4 while Scr and urea nitrogen cannot early and effective monitoring of the occurrence of AKI, which makes it urgent for early diagnostic markers of AKI to monitor renal function, early intervention and treatment of AKI to improve the prognosis of patients and reduce mortality.

To summarize, addressing these concerns will improve the reliability of the research findings and their clinical application prospects in routine clinical practice.

Abbreviations

AKI, Acute kidney injury; Scr, serum creatinine; NGAL, neutrophil gelatinase-associated lipocalin; KIM-1, kidney injury molecule-1; HO-1, heme oxygenase-1; CPB, cardiopulmonary bypass.

Funding

Funded by Scientific research project of Ningxia Education Department (NO: NYG2022047).

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Zhang B, Song YY, Ma Q, et al. Expression and Significance of KIM-1, NGAL and HO-1 in patients with acute kidney injury after cardiac valve replacement. J Inflamm Res. 2023;16:2755–2761. doi:10.2147/JIR.S410338

2. Wang YY, Dai L, Yang N, et al. 体外循环心脏不停跳二尖瓣置换术围术期肾损伤分子-1的变化 [Changes in molecule-1 of renal injury during perioperative cardiac non-stop jump mitral valve replacement on cardiopulmonary bypass]. Guangxi Med. 2015;37(7):913–918.

3. Cai Y, Li BL, Sun HP, et al. 肾损伤分子-1表达水平在成人心脏体外循环术后急性肾损伤早期诊断中的价值 [The value of kidney injury molecular-1 expression level in the early diagnosis of acute kidney injury after adult cardiac cardiopulmonary bypass]. Shanghai Med. 2015;38(5):913–918.

4. Jiang Y, Song YY. Analysis of risk factors and intervention strategies for acute kidney injury after cardiac valve replacement. J Inflammation Res. 2023;16:3523–3529. doi:10.2147/JIR.S425485

Creative Commons License © 2024 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.